Zydus Lifesciences' Ahmedabad Facility Passes USFDA Inspection with Minor Observations
Zydus' Ahmedabad unit completes USFDA inspection
Business Standard
Image: Business Standard
Zydus Lifesciences' Unit 9 at Zydus Biotech Park in Changodar, Ahmedabad, underwent a USFDA Good Manufacturing Practices (GMP) inspection from April 27 to May 5, 2026, resulting in seven observations but no data integrity issues. The company aims to address these observations promptly.
- 01Zydus Lifesciences' Unit 9 in Ahmedabad was inspected by the USFDA.
- 02The inspection took place from April 27 to May 5, 2026.
- 03Seven observations were noted, with no data integrity concerns.
- 04The company plans to work closely with the USFDA to resolve the observations.
- 05This inspection is part of routine oversight to ensure compliance with manufacturing standards.
Advertisement
In-Article Ad
Zydus Lifesciences has announced the completion of a Good Manufacturing Practices (GMP) inspection by the United States Food and Drug Administration (USFDA) at its Unit 9 facility located in Zydus Biotech Park, Changodar, Ahmedabad. The inspection took place from April 27 to May 5, 2026, and concluded with seven observations. Importantly, there were no observations related to data integrity, which is a critical aspect of regulatory compliance. Zydus Lifesciences is committed to addressing these observations swiftly and will collaborate closely with the USFDA to ensure all concerns are resolved. This inspection reflects the ongoing regulatory oversight that pharmaceutical companies must navigate to maintain high manufacturing standards.
Advertisement
In-Article Ad
The inspection results may influence Zydus Lifesciences' production capabilities and regulatory standing, which could affect local employment and product availability.
Advertisement
In-Article Ad
Reader Poll
How important is regulatory compliance for pharmaceutical companies?
Connecting to poll...
More about Zydus Lifesciences
Read the original article
Visit the source for the complete story.